ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)lowering efficacy of the drug. In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin.
著者Tomlinson B, Hu M, Lee VWY, Lui SSH, Chu TTW, Poon EWM, Ko GTC, Baum L, Tam LS, Li EK
期刊名稱Clinical Pharmacology and Therapeutics
出版年份2010
月份5
日期1
卷號87
期次5
出版社NATURE PUBLISHING GROUP
頁次558 - 562
國際標準期刊號0009-9236
電子國際標準期刊號1532-6535
語言英式英語
Web of Science 學科類別Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2020-28-10 於 00:25